Biotech Values

[apljack]

Re: JAV

Bladerunner, I can't imagine mgmt trying to go it alone, particularly since they're on record about looking for partners and stating publicly that there has been an increase` in unsolicited interest from outside partners. Going it alone would mean they've failed miserably in getting a partner and would lose what limited credibility they currently have.

Biopete's post notwithstanding, I think that we will continue to bounce at this price range as mgmt buys at $2.41 in the recent private placement appears to have established the bottom. I agree with biopete that sales will come in light of the $220K estimate, but not by much. P3 data will see a boost in interest. I still believe that Dyloject will ultimately replace Toradol in most hospital practices and be a $200-300 million drug in a couple of years. PMI-150 will also find that type of market share for breakthrough pain, both in post-op and cancer settings.

Downside here is minimal, I'd be buying if I had some spare cash.

aj